NCT04944082 is a Phase 4 clinical trial of Ivermectin in Covid19, sponsored by Assiut University.

Who is sponsoring NCT04944082?

NCT04944082 is sponsored by Assiut University.

What drugs are being tested in NCT04944082?

Interventions in NCT04944082: Ivermectin.

Is NCT04944082 still recruiting?

NCT04944082 is currently status unknown. Last updated 29 June 2021.

Last reviewed 2021-06-29 · How we verify

NCT04944082

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Remdesivir- Ivermectin Combination Therapy in Severe Covid-19

Status unknown Phase 4 Last updated 29 June 2021

What this trial tests

Phase 4 trial testing Ivermectin in Covid19 in 60 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Assiut University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 July 2021
Primary completion	31 December 2021
Estimated completion	31 December 2021

Drugs / interventions tested

Ivermectin (ivermectin) — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Assiut University

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recent study reported in vitro synergistic interaction between two FDA approved drugs, remdesivir (RDV) and ivermectin (IVM) resulting in enhanced antiviral activity against SARS-CoV-2, the causative pathogen of COVID-19. The aim of the current study is comparing the efficacy and safety of combining remdesivir and ivermectin versus using remdesivir alone in patients with severe COVID-19.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Ivermectin for preventing and treating COVID-19.
Popp M, Reis S, Schießer S, Hausinger RI, et al · · 2022 · cited 30× · PMID 35726131 · DOI 10.1002/14651858.cd015017.pub3

Verify or expand the search:

Other trials of Ivermectin

Trials testing the same drug.

NCT07396714 — the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts. · EARLY_PHASE1 · not yet recruiting
NCT07145736 — Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical · Phase 4 · recruiting
NCT05605925 — Ivermectin-artemisinin Combination Therapy for Eradication of Malaria · Phase 4 · unknown
NCT05045937 — Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19 · unknown
NCT05643820 — Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis · Phase 1 · completed

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04944082 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 29 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04944082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing